Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

CART BP Pro-ohjattu verenpaineen hallinta potilailla, joilla on hallitsematon hypertensio: monikeskuksinen satunnaistettu kontrolloitu tutkimus (CART-BP RCT)

maanantai 9. marraskuuta 2026 päivittänyt: Hyung Joon Joo, Korea University Anam Hospital

Cuffittoman ambulantin verenpaineen seurantalaitteen ohjaaman verenpaineenhoidon tehokkuus ja turvallisuus verrattuna tavanomaiseen hoitoon korealaisilla kontrolloimattoman korkean verenpaineen potilailla: monikeskuksellinen prospektiivinen satunnaistettu kontrolloitu tutkimus

This multicenter, prospective, open-label randomized trial compares CART BP Pro-guided blood pressure management with usual care based on office blood pressure in Korean adults with uncontrolled hypertension. The planned enrollment is 400 participants at three Korea University hospitals. Participants are assigned in a 1:1 ratio to the two groups. CART BP Pro is a ring-type device that estimates blood pressure from optical pulse signals. Both groups receive guideline-based antihypertensive care.

The main outcome is the difference between groups in CART-derived, time-weighted 24-hour mean systolic blood pressure at the 24-week assessment, with an allowable assessment window of 16-32 weeks. Both groups undergo outcome assessment. Recording-quality rules allow some incomplete recordings, including early device return, while requiring sufficient duration and time coverage. Standardized office blood pressure, office blood pressure below 130/80 mmHg, other CART blood pressure measures, and adverse events are also assessed.

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Ehdot

Yksityiskohtainen kuvaus

Hypertension remains one of the most prevalent chronic conditions worldwide and is a major contributor to cardiovascular morbidity and mortality. Although multiple antihypertensive medications are widely used, a substantial proportion of patients remain inadequately controlled. Office blood pressure measurements alone may not adequately reflect the true blood pressure burden or nocturnal blood pressure patterns. Ambulatory blood pressure monitoring provides a more comprehensive assessment of blood pressure variability and control but is limited by patient discomfort and practical constraints. Recently developed wearable cuffless blood pressure monitoring devices have the potential to provide continuous and convenient blood pressure assessment in real-world settings.

CART BP Pro is a wearable ring-type device that uses photoplethysmography-based technology to estimate continuous ambulatory blood pressure. Compared with conventional cuff-based ambulatory blood pressure monitoring, the device allows more comfortable long-term monitoring and may facilitate improved hypertension management.

This study is designed as a multicenter, prospective, open-label randomized controlled trial conducted at Korea University Anam Hospital, Korea University Guro Hospital, and Korea University Ansan Hospital. Adult patients with uncontrolled hypertension despite ongoing antihypertensive therapy will be enrolled and randomized to either CART BP Pro-guided management or usual care. In the intervention group, antihypertensive treatment adjustments will be guided by blood pressure information obtained from the CART BP Pro device. In the control group, treatment decisions will be based on conventional office blood pressure measurements according to standard clinical practice. The main blood pressure and safety assessment targets 24 weeks, with an allowable assessment window of 16-32 weeks. An optional extended follow-up to 48 weeks may be performed for additional observational analysis.

The study aims to determine whether CART BP Pro-guided blood pressure management improves ambulatory blood pressure control compared with usual care in real-world clinical practice.

Assessment timing and selection Randomization is Day 0. The target assessment is Day 168, with an allowable window of Days 112-224, inclusive. If multiple valid CART assessments are available, the assessment closest to Day 168 is selected; ties are resolved using the earlier assessment. Baseline CART monitoring is not required and its availability is not an eligibility condition for the primary analysis. Standardized upper-arm cuff office BP is assessed in both groups within the same follow-up window; an available office BP outcome is not discarded solely because CART monitoring is missing.

Recording calculation and quality control Monitoring targets 24 hours. The designated 24-hour window begins at the documented recording start and is divided into 24 consecutive 1-hour intervals. For each interval with at least one valid BP report, the interval mean is calculated. The time-weighted 24-hour estimate is the sum of available hourly means divided by the number of evaluable intervals, not by 24 when intervals are missing. Empty intervals are not set to zero or filled for this calculation. This is an estimate based on observed time intervals, not a reconstruction of unobserved BP.

For the primary analysis, recordings must have a recording duration of at least 20 hours, at least 17 evaluable hourly intervals, and no within-recording unobserved gap longer than 4 hours. Recording duration and within-recording gaps are determined from documented recording/device application and removal times when available. Time confirmed to occur after device removal is not counted as a within-recording signal-loss gap. When application/removal times are unavailable, the first-to-last valid-report span within the designated window is used as a duration proxy, with its limitation documented; early return is not inferred solely from the last BP report. Gaps while the device remains worn, including the start or end of the worn period when known, are distinguished from post-removal non-observation. Exact duplicate reports are removed, and timestamp conflicts or apparent technical errors are reviewed under documented data-cleaning rules. The same operational QC rules apply to both groups and all sites. These are study-defined criteria, not externally validated CART recording-quality standards.

Sleep and awake periods Period-specific BP outcomes use the participant sleep diary. In the export, a sleep label denotes asleep and a blank denotes awake. Sleep labels, unusually long sleep periods, and discrepancies are checked against the diary. Short or poor sleep alone is not a primary-recording QC failure. If the diary indicates sleep but no BP was captured during that period, timing and technical completeness are reviewed. The evaluability of sleep-period BP and dipping outcomes is considered separately from the 24-hour primary outcome. Follow-up sleep duration is not a covariate in the primary treatment-effect model.

Analysis and sensitivity analyses The primary observed-data analysis compares eligible follow-up CART SBP outcomes according to original randomized assignment, regardless of subsequent treatment changes. ANCOVA includes randomized group, pre-randomization office SBP, and study site. The study uses non-stratified block randomization; site is a baseline adjustment variable, not a randomization stratum. Post-randomization visit counts and medication intensification are not included as primary-model covariates. Participants without an evaluable primary outcome are not described as having an observed outcome. Missing-outcome counts and reasons, and recording QC failures, are reported by group and site; observed-data analysis does not by itself remove selection bias from missing outcomes.

Two recording-quality sensitivity analyses repeat the outcome comparison: (1) stricter recordings with at least 20 hours duration, at least 20 evaluable hourly intervals, and no within-recording gap longer than 3 hours; and (2) a relaxed recording criterion requiring at least 17 evaluable hourly intervals without the additional primary duration/gap restrictions. Separate missing-outcome sensitivity methods will be specified in the statistical analysis plan; they are distinct from the recording-quality comparisons and do not change measured values into imputed observations.

Secondary and exploratory outcomes The office SBP component of office BP change and office BP below 130/80 mmHg are key secondary efficacy outcomes. Additional secondary outcomes include 24-hour DBP, awake/asleep SBP and DBP, and the proportion with CART-derived 24-hour mean BP below conventional ABPM reference thresholds. BP load is retained as an exploratory outcome rather than deleted. Applying conventional ABPM thresholds to CART-derived values does not validate device-specific diagnostic thresholds. Safety observation continues from randomization through the designated final study assessment visit; actual observation duration is reported. Medication dose reduction alone is not an adverse event; the associated symptom or clinical abnormality, if present, is the event and the dose reduction is an action taken.

Registry clarification The operational recording-quality and endpoint-calculation details are clarified in this November 2026 registry update during the ongoing study. This update does not establish that these details were included at study initiation or replace the protocol/SAP amendment and ethics-review process.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

400

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

      • Ansan, Etelä -Korea
        • Rekrytointi
        • Korea University Ansan Hospital
        • Ottaa yhteyttä:
        • Päätutkija:
          • Seung Yong Shin, MD PhD
      • Seoul, Etelä -Korea, 02841
        • Rekrytointi
        • Korea University Anam Hospital
        • Ottaa yhteyttä:
        • Päätutkija:
          • Hyung Joon Joo, MD PhD
        • Alatutkija:
          • Cheol Woong Yu, MD PhD
        • Alatutkija:
          • Dong-Hyuk Cho, MD PhD
        • Alatutkija:
          • Jung-Joon Cha, MD PhD
        • Alatutkija:
          • Mi-Na Kim, MD PhD
        • Alatutkija:
          • Jae Hyoung Park, MD PhD
        • Alatutkija:
          • Se Won Oh, MD PhD
      • Seoul, Etelä -Korea
        • Rekrytointi
        • Korea University Guro Hospital
        • Ottaa yhteyttä:
          • Soohyung Park, MD PhD
          • Puhelinnumero: +82-1031053710
          • Sähköposti: shp503@naver.com
        • Päätutkija:
          • Soohyung Park, MD PhD
        • Alatutkija:
          • Ji Eun Lee, MD

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

19 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  1. Age ≥ 19 years
  2. Uncontrolled hypertension defined as office systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg
  3. Ability and willingness to provide written informed consent and comply with study procedures

Exclusion Criteria:

  1. History of intolerance or contraindication to olmesartan, amlodipine, or hydrochlorothiazide
  2. Suspected secondary hypertension
  3. Atrial fibrillation
  4. Pregnancy or lactation
  5. Any serious medical condition that may interfere with study participation or interpretation of study results

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: CART BP Pro-guided blood pressure management

Participants will undergo ambulatory blood pressure monitoring using the CART BP Pro wearable device. Antihypertensive medication adjustments will be guided by ambulatory blood pressure data obtained from the device.

CART BP Pro is a wearable cuffless continuous blood pressure monitoring device based on photoplethysmography technology that enables 24-hour ambulatory blood pressure measurement.

Active Comparator: Usual care

Participants will receive standard hypertension management based on office blood pressure measurements according to current clinical guidelines.

Antihypertensive medication adjustments are based on office blood pressure measurements obtained during routine outpatient visits.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
24-hour mean systolic blood pressure measured with CART BP Pro
Aikaikkuna: 24 weeks after randomization (target Day 168; allowable window Days 112-224)

Between-group difference in CART BP Pro-derived, time-weighted mean systolic blood pressure (SBP; mmHg). Monitoring targets 24 hours. The designated 24-hour window is divided into consecutive 1-hour intervals; valid BP reports are averaged within each interval and available hourly means are then averaged with equal weight. Primary recording QC requires a recording duration of at least 20 hours, at least 17 evaluable hourly intervals (at least one valid BP report each), and no within-recording unobserved gap longer than 4 hours. Confirmed time after device removal is not an internal recording gap. Missing intervals are not set to zero or filled for this calculation. Baseline CART measurement is not required. The valid assessment closest to Day 168 within Days 112-224 is selected; ties use the earlier assessment.

24 weeks after randomization (target Day 168; allowable window Days 112-224)

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in office systolic and diastolic blood pressure
Aikaikkuna: 24 weeks after randomization (target Day 168; allowable window Days 112-224)

Change in standardized upper-arm cuff office systolic and diastolic blood pressure (mmHg) from baseline to the selected 24-week assessment. The systolic blood pressure component is a key secondary efficacy outcome; the diastolic component is an additional secondary outcome. Between-group systolic comparisons adjust for baseline office systolic blood pressure and study site. The same standardized measurement procedure is used in both groups.

24 weeks after randomization (target Day 168; allowable window Days 112-224)
Office blood pressure below 130/80 mmHg
Aikaikkuna: 24 weeks after randomization (target Day 168; allowable window Days 112-224)

Key secondary efficacy outcome: proportion of participants with standardized upper-arm cuff office systolic blood pressure less than 130 mmHg and diastolic blood pressure less than 80 mmHg at the selected 24-week assessment. Both conditions must be met. The same standardized measurement procedure is used in both groups.

24 weeks after randomization (target Day 168; allowable window Days 112-224)
Incidence of treatment-emergent adverse events (TEAEs)
Aikaikkuna: From randomization through the final study assessment visit (target 24 weeks; allowable assessment window 16-32 weeks)

Proportion of participants with at least one treatment-emergent adverse event, collected from randomization through the designated final study assessment visit. Events, severity, seriousness, relatedness, and resulting treatment changes are recorded. Medication dose reduction alone is not an adverse event; an associated symptom or clinical abnormality is recorded as the event, with dose reduction recorded as an action taken. Actual safety observation duration is reported by group.

From randomization through the final study assessment visit (target 24 weeks; allowable assessment window 16-32 weeks)
CART BP Pro-derived 24-hour blood pressure below conventional ABPM reference thresholds
Aikaikkuna: 24 weeks after randomization (target Day 168; allowable window Days 112-224)

Proportion of participants whose time-weighted CART BP Pro-derived 24-hour mean systolic blood pressure is less than 130 mmHg and mean diastolic blood pressure is less than 80 mmHg; both conditions must be met. This applies conventional ambulatory blood pressure monitoring (ABPM) reference thresholds to CART-derived measurements and is not a validation of device-specific diagnostic thresholds.

24 weeks after randomization (target Day 168; allowable window Days 112-224)
Mean awake and asleep systolic and diastolic blood pressure measured with CART BP Pro
Aikaikkuna: 24 weeks after randomization (target Day 168; allowable window Days 112-224)

CART BP Pro-derived mean systolic and diastolic blood pressure (mmHg), reported separately for diary-defined awake and asleep periods using available hourly means within each period. In the export, a sleep label indicates asleep and a blank indicates awake. Period-specific evaluability is assessed separately from the 24-hour primary endpoint. Short or poor sleep alone does not invalidate an otherwise evaluable primary recording.

24 weeks after randomization (target Day 168; allowable window Days 112-224)
24-hour mean diastolic blood pressure measured with CART BP Pro
Aikaikkuna: 24 weeks after randomization (target Day 168; allowable window Days 112-224)

Between-group difference in CART BP Pro-derived, time-weighted 24-hour mean diastolic blood pressure (DBP; mmHg). Valid DBP reports are averaged within each 1-hour interval and available hourly means are averaged with equal weight. The same recording window, assessment selection rule, and primary recording QC criteria used for the primary SBP endpoint are applied.

24 weeks after randomization (target Day 168; allowable window Days 112-224)

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
24-hour blood pressure load
Aikaikkuna: 24 weeks after randomization (target Day 168; allowable window Days 112-224)

Exploratory percentage of valid CART BP Pro blood pressure reports exceeding the protocol-defined systolic or diastolic blood pressure thresholds during the monitoring period. This recording-level BP load measure is distinct from the time-weighted mean blood pressure endpoint.

24 weeks after randomization (target Day 168; allowable window Days 112-224)

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Keskiviikko 22. lokakuuta 2025

Ensisijainen valmistuminen (Arvioitu)

Torstai 31. joulukuuta 2026

Opintojen valmistuminen (Arvioitu)

Lauantai 31. heinäkuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 6. maaliskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 6. maaliskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Torstai 12. maaliskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 12. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 9. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

IPD-suunnitelman kuvaus

De-identified individual participant data collected in this study will not be shared with external researchers at this time. Data sharing may be considered in the future subject to institutional review board approval and institutional data governance policies.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa